H.C. Wainwright raised the firm’s price target on ADC Therapeutics to $9 from $3 and keeps a Buy rating on the shares. The analyst says “encouraging” activity has been seen in LOTIS-7 and for ADCT-601.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ADCT:
